TUESDAY 26 SEPTEMBER
PPM-001 – Oncological patients’ perception of biological medicines switching by a physician
MSc (Pharm) Anniina Kössi1, Dr Maarit Dimitrow1, Dr Marika Pohjanoksa-Mäntylä1, Dr Santtu Mikkonen2, Professor Marja Airaksinen1, Dr Kari Linden3
1 Social and Clinical Pharmacy, Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland, 2Department of Applied Physics, University of Eastern Finland, Kuopio, Finland, 3Research Unit, University Pharmacy (Yliopiston Apteekki), Helsinki, Finland
PPM-002 Clinical efficacy and safety of Tigecycline based on therapeutic drug monitoring for carbapenem- resistant gram negative bacterium pneumonia in intensive caare units
Mr Xiangrong Bai1
1Xuanwu Hospital Capital Medical University, Beijing, China
PPM-003 Assessing the readability of discharge medication records prepared at The Prince Charles Hospital: A retrospective study
Ms Georgina Dowling1, Ms Sheba Alex2, Mr Jaryth Twine1, Ms Faith Yong3,4,5
1Pharmacy Department, The Prince Charles Hospital, Metro North Health, Queensland Health, Brisbane, Australia, 2Queensland University of Technology, Faculty of Health, School of Clinical Sciences, Brisbane, Australia , 3Faculty of Medicine, University of Queensland, Herston, Brisbane, Australia, 4Westmead Institute of Medical Research, University of Sydney, Sydney, Australia, 5Faculty of Medicine and Health, University of New South Wales, Sydney, Australia
PPM-004 Analysis of the rate of formation of 4-hydroxycyclophosphamide in dried blood spot of breast cancer patients in Indonesia after administration of cyclophosphamide
Prof Yahdiana Harahap1
1Universitas Indonesia, Depok, Indonesia, 2Republic of Indonesia Defense University, Bogor, Indonesia
PPM-005 How to dose edoxaban when taking ritonavir-boosted medications for COVID-19 infections in different patient populations
Dr Qingfeng He1, Mr Hao Xue2
1School of Pharmacy, Fudan University, Shanghai, China, 2Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
PPM-006 Study of rivaroxaban and crizotinib drug-drug interaction and dose recommendation based on PBPK model
Fuhai Hui1, Mingyi Zhao1
1Shenyang Pharmaceutical University, Shenyang, China
PPM-007 Lansoprazole as a promising concomitant agent ameliorating cisplatin-induced ototoxicity
Dr Kenji Ikemura1, Dr Eri Wakai2, Prof Yuhei Nishimura3, Prof Masahiro Okuda1
1Department of Pharmacy, Osaka University Hospital, Suita, Japan, 2Division of Glocal Pharmacology, Department of Pharmacology, Graduate School of Medicine, Osaka University, Suita, Japan, 3Department of Integrative Pharmacology, Mie University Graduate School of Medicine, Tsu, Japan
PPM-008 Potential benefits of local radiotherapy in addition to adjuvant chemotherapy in female patients with triple negative breast cancer in the absence of distant metastases: a SEER database analysis
Ms Shubing Jia1, Mingyi Zhao1
1Shenyang Pharmaceutical University, Shenyang, China
PPM-009 Pharmacokinetic/Pharmacodynamic target attainment of tigecycline in patients with hepatic impairment in a real-world setting
Mr Lu Jin1, MS. Xuemei Luo1, Mr. Huaijun Zhu1, Prof Wei-hong Ge1
1Department Of Pharmacy, Nanjing Drum Tower Hospital, Nanjing, China
PPM-010 The role of a clinical pharmacist in the treatment and management of psychotic and bipolar disorders
Ms Kudzai Daisy Kahwenga1, Professor Elmien Bronkhorst1, Ms Lindiwe Mnukwa1
1Sefako Makgatho Health Sciences University, Johannesburg, South Africa
PPM-011 Risk factors associated with unplanned acute care in outpatient chemotherapy with oral anticancer drugs as monotherapy or combination therapy with injectable anticancer drugs
Dr Yohei Kawano1, Dr Kenji Kawasumi2, Prof Yasunari Mano1, Dr Reiko Matsui2, Dr Ayako Maeda-Minami1, Dr Yuichiro Yamamoto1, Prof Kenichi Negishi3, Dr Shuji Shimada1, Dr Masashi Nagata4, Prof Takao Aoyama1
1Tokyo University of Science, Noda-shi Chiba, Japan, 2National Cancer Center Hospital East, Kashiwa-shi Chiba, Japan, 3Kitasato University, Minato-ku Tokyo, Japan, 4Tokyo Medical and Dental University Hospital, Bunkyo-ku Tokyo, Japan
PPM-012 Audit on use of Zuclopenthixol Acetate for Acute Behavioural Disturbance Management in mental health in-patients
Ms Aislinn Kennedy1
1Royal Brisbane And Women’s Hospital, Brisbane, Australia
PPM-013 Preparation of medicines by three-dimensional printing and personalization of therapy in compounding pharmacies: a case study
Ms Sara Figueiredo1,2, Dr. Ana I Fernandes3, Mr Nuno Cardoso4, Dr. Fátima Godinho Carvalho1, Dr. João F Pinto2
1LEF – Infosaúde, Barcarena, Portugal, 2Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal, 3CiiEM – Egas Moniz School of Health and Science, Monte de Caparica, Portugal, 4ANF, Lisboa, Portugal
WEDNESDAY 27 SEPTEMBER
PPM-015 The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation
Prof Xiaoye Li1, Dr Zi Wang1, Prof. Qing Xu1, Prof. Xiaoyu Li1, Prof. Qianzhou Lv1
1Zhongshan Hospital, Fudan University, Shanghai, China
PPM-016 Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients
Prof Xiaoye Li1
1Zhongshan Hospital, Fudan University, Shanghai, China
PPM-017 Exploring G-protein coupled receptors as specific targeting sites for drug delivery into ovarian cancer cells
Ms Riya Khetan1, Dr Ian Johnson1, Dr Preethi Eldi1, A/Prof Anton Blencowe1, Professor Sanjay Garg1, Dr Hugo Albrecht1
1University Of South Australia, Adelaide, Australia
PPM-018 Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines
Ms Cindy Lau1,2, Prof Deborah Marriott3,4, Dr Hayley Shultz5, Dr Michael Gould6, Dr David Andresen3,6, Prof Sebastian Wicha7, Prof Jan-Willem Alffenaar2,8,9, Dr Jonathan Penm2,10, A/Prof Stephanie Reuter Lange5
1Pharmacy Department, St Vincent’s Hospital Sydney, Sydney, Australia, 2School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia, 3Department of Clinical Microbiology and Infectious Diseases, St Vincent’s Hospital Sydney, Sydney , Australia, 4School of Medicine, University of New South Wales,, Sydney , Australia, 5UniSA Clinical & Health Sciences, University of South Australia, Adelaide, Australia, 6School of Medicine, University of Notre Dame, Sydney, Australia, 7Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany, 8Department of Pharmacy, Westmead Hospital, Sydney, Australia, 9Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, Sydney, 10Department of Pharmacy, Prince of Wales Hospital, Sydney, Australia
PPM-019 A systematic review of knowledge, attitudes, perspectives and education needs in oncology pharmacogenomics among healthcare professionals and consumers
Dr Chiao Xin Lim1, Mr Alistair Bozkurt1, Ms Zi Yue Chen1, Ms Abbey Hird1, Ms Joanne Wickens1, Ms Smaro Lazarakis2, A/Prof Safeera Hussainy3,4,5, Dr Marliese Alexander3,4
1Pharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia, 2Health Sciences Library, Royal Melbourne Hospital, Parkville, Australia, 3Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Australia, 4Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia, 5Department of General Practice, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
PPM-020 Pharmacogenetics of warfarin dosing in Chinese adults
with nonvalvular atrial fibrillation
Mrs Jia Liu1
1Northern Jiangsu People’s Hospital, Yangzhou, China
PPM-021 FIRTECH, a novel infrared patch for the non-pharmacological management of acute mild-to-moderate low back pain: Data from randomized phase 1 and 3 trials
Dr Joyce McSwan1, Dr Perola Grinberg Plapler2, Dr Ali Mobasheri3, Dr Michael Richard Hamblin4, Mr Bill Giannakopoulos5, Dr Valentine Polivka6, Dr Mohamed Amessou7, Dr Simon Hitier7, Dr Rafael Varona7, Dr Jeffrey Gudin8, Dr Gisele Pickering9
1GCPHN Persistent Pain Program, PainWISE, Gold Coast, Queensland, Australia, 2Division of Physical Medicine, Institute of Orthopedics and Traumatology, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, São Paulo, Brazil, 3Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland, 4University of Johannesburg, Johannesburg, South Africa, 5Sanofi CHC, Scientific Innovation , Athens, Greece, 6AIXIAL Group an ALTEN company, Boulogne-Billancourt, France, 7Sanofi CHC, Consumer Safety and Evidence, Gentilly, France, 8Department of Anesthesiology, University of Miami, Miller School of Medicine, Miami, Florida, United States of America, 9Platform of Clinical Investigation–Inserm CIC 1405; C.H.U. of Clermont-Fd, 63003, Clermont-Ferrand Cedex, France
PPM-022 Personalised dose titration regimens through 3D printing medicines
Dr Jared Miles1, Mr Liam Krueger1, Zheng Zheng1, Jason Ward1, Prof Amirali Popat1
1University of Queensland, Woolloongabba, Australia
PPM-023 Using machine learning algorithm to predict the occurrence of nephrotoxicity with tacrolimus
Ms Tsubura Noda1, Mr. Shotaro Mizuno1, Ph.D. Takeshi Hase2, Ph.D. Kaoru Mogushi2, Mr. Yoritsugu Iida2, Ph.D. Yasuyoshi Ishiwata3, Dr Masashi Nagata1,3
1Department of Pharmacokinetics and Pharmacodynamics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 2Innovative Human Resource Development Division, Institute of Education, Tokyo Medical and Dental University, Tokyo, Japan, 3Department of Pharmacy, Tokyo Medical and Dental University Hospital, Tokyo Medical and Dental University, Tokyo, Japan
PPM-024 Trimethoprim-sulfamethoxazole pharmacokinetic evaluation in adult kidney transplant receipients
Ms Carla Scuderi1, Dr Sadia Jahan1, Dr Suzanne Parker2, Mrs Margaret Jacks, Dr George John1, Prof Andrew Mallett3, Dr Helen Healy1, Prof Jason Roberts1, a/Prof Christine Staatz4
1RBWH, Qld Health, Brisbane, Australia, 2UQ Centre for Clinical Research, Faculty of Medicine, UQ, Brisbane, Australia, 3Townsville University Hospital, Townsville, Australia, 4Pharmacy School, UQ, Brisbane, Australia
PPM-025 Measuring adherence in patients with metastatic breast cancer on CDK4/6 inhibitors therapy using the MARS-5 questionnaire and LC-MS/MS
Matea Baković1,2, Magdalena Krajinović1, Lucija Benić1, Lu Turković1, PhD Tajana Silovski3, Prof. Natalija Dedić Plavetić3,4, Prof Maja Ortner Hadžiabdić1, Prof Miranda Sertić1
1University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia, 2PrimeVigilance d.o.o., Zagreb, Croatia, Zagreb, Croatia, 3University Hospital Centre Zagreb, Zagreb, Croatia, 4University of Zagreb, Scool of Medicine, Zagreb, Croatia
PPM-026 Validating a novel three-times weekly post-haemodialysis cefazolin regimen in Indigenous Australian patients– a population pharmacokinetic study
Ms Carleigh Tongs1, Dr Suzanne Parker2, Miss Betty Zam3, Dr Fabian Chiong4,5, Dr Cherian Sajiv6, Dr Basant Pawar6, Dr Aadith Ashok7, Ms Brynley Cooper8, Dr Steven Tong9,10, Dr Sonja Janson11, Dr Steven Wallis2, Prof Jason Roberts2,12,13,14,15, Dr Danny Tsai1,2,8
1College of Medicine and Public Health, Flinders University, Darwin , Australia, 2University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Australia, 3Pharmacy Department, Alfred Health, Melbourne, Australia, 4Department of Medicine, Alice Springs Hospital, Alice Springs, Australia, 5Department of Infectious Diseases, Canberra Hospital, Canberra, Australia, 6Department of Nephrology, Alice Springs Hospital, Alice Springs, Australia, 7Department of Infectious Diseases, Alfred Health, Melbourne, Australia, 8Pharmacy Department, Alice Springs Hospital, Alice Springs, Australia, 9Victorian Infectious Diseases Service, The Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia, 10Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia, 11Department of Infectious Diseases, Royal Darwin Hospital, Darwin, Australia, 12Department of Intensive Care Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Australia, 13School of Pharmacy, The University of Queensland, Brisbane, Australia, 14Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia, 15Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France
PPM-027 Study the individual differences of patients with rheumatoid arthritis to methotrexate therapy based on metabolomics
Dr Min Wang1, Dr Qing Shu, Prof Wei-hong Ge
1The Affiliated Drum Tower Hospital Of Nanjing University Medical School, Jiangsu, China
PPM-028 The impact of nicotine metabolism on smoking cessation during pregnancy: A review
Ms Min-Tz Weng1, Dr. Angela Ratsch2, Dr. Jared A Miles1, Associate Professor Kathryn J Steadman1
1The University Of Queensland, Brisbane, Australia, 2Wide Bay Hospital and Health Services, Hervey Bay, Australia
PPM-029 Impact of supportive care crugs on treatment effectiveness in cancer chemotherapy
Kenta Yagi1,2, Dr Fuka Aizawa2,3, Dr. Takahiro Niimura1,2, Mr. Akinori Maruo4, Dr. Yuki Izawa-Ishizawa2,5, Dr Hirofumi Hamano4, Dr. Mitsuhiro Goda2,3, Prof Yoshito Zamami4, Professor Keisuke Ishizawa1,2,3
1Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan, 2Department of Clinical Pharmacology and Therapeutics, University of Tokushima Graduate School of Biomedical Sciences, Tokushima, Japan, 3Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan, 4Department of Pharmacy, Okayama University Hospital, Okayama, Japan, 5Department of General Medicine, Taoka Hospital, Tokushima, Japan
